Abstract
Here we describe a series of methods that can be used to assess the activities of “vaccines,” drugs, and genetically modified vectors, for their abilities to inhibit transmission of Plasmodium from its vertebrate to its mosquito hosts. The selection of method to be used is determined by the purpose of the experiment, which can include the determination of the site/time of activity, and/or the potential reduction in transmission achieved.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sinden RE (2010) A biologist’s perspective on malaria vaccine development. Hum Vaccin 6:3–11
Rosenberg R (2008) Malaria: some considerations regarding parasite productivity. Trends Parasitol 24:487–491
Butcher GA (1997) Antimalarial drugs and the mosquito transmission of Plasmodium. Int J Parasitol 27:975–987
Sauerwein RW (2007) Malaria transmission-blocking vaccines: the bonus of effective malaria control. Microbes Infect 9:792–795
Carter R (2001) Transmission blocking malaria vaccines. Vaccine 19:2309–2314
Malkin EM et al (2005) Phase I clinical trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23:3131–3138
Stowers A, Carter R (2001) Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1:619–628
Wu Y et al (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 3:e2636
LeBlanc R et al (2008) Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 26:185–192
Lobo CA et al (1999) Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 67:1688–1693
Blagborough AM et al (2010) Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28:6014–6020
Miyata T et al (2011) Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine 29:2720–2726
Franke-Fayard B et al (2004) A Plasmodium berghei reference line that constitutively expresses GFP at a high level throughout the complete life cycle. Mol Biochem Parasitol 137:23–33
Janse CJ et al (2006) High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol Biochem Parasitol 145:60–70
Ramjanee S et al (2007) The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25:886–894
Mlambo G et al (2008) Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect Immun 76:2018–2024
Delves MJ, Sinden RE (2010) A semi-automated method for counting fluorescent malaria oocysts increases the throughput of transmission blocking studies. Malar J 29:9–35
Sinden RE et al (2007) Progression of Plasmodium berghei through Anopheles stephensi is density-dependent. PLoS Pathog 3:e195
Vaid A, Sharma P (2006) PfPKB, a protein kinase B-like enzyme from Plasmodium falciparum: II. Identification of calcium/calmodulin as its upstream activator and dissection of a novel signalling pathway. J Biol Chem 281:27126–27133
Winger LA et al (1988) Ookinete antigens of Plasmodium berghei. Appearance on the zygote surface of an Mr 21 kDa determinant identified by transmission-blocking monoclonal antibodies. Parasite Immunol 10:193–207
Ponnudurai T et al (1986) Synchronization of Plasmodium falciparum gametocytes using an automated suspension culture system. Parasitology 93:263–274
Graves PM et al (1984) Gametocyte production in cloned lines of Plasmodium falciparum. Am J Trop Med Hyg 33:1045–1050
Ifediba T, Vanderburg JP (1981) Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294:364–366
Read M, Hyde JE (1993) Simple in vitro cultivation of the malaria parasite Plasmodium falciparum (erythrocytic stages) suitable for large-scale preparations. Methods Mol Biol 21:43–55
Brown KN, Hills LA (1981) Erythrocyte destruction and protective immunity to malaria: enhancement of the immune response by phenylhydrazine treatment. Tropenmed Parasitol 32:67–72
van den Berghe L (1954) The history of the discovery of Plasmodium berghei. Indian J Malariol 8:241–243
Vincke IH (1954) Natural history of Plasmodium berghei. Indian J Malariol 8:245–256
Yoeli M (1965) Studies on Plasmodium berghei in nature and under experimental conditions. Trans R Soc Trop Med Hyg 59:255–276
Bray RS (1954) The mosquito transmission of Plasmodium berghei. Indian J Malariol 8:263–274
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Blagborough, A.M., Delves, M.J., Ramakrishnan, C., Lal, K., Butcher, G., Sinden, R.E. (2012). Assessing Transmission Blockade in Plasmodium spp.. In: Ménard, R. (eds) Malaria. Methods in Molecular Biology, vol 923. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-026-7_40
Download citation
DOI: https://doi.org/10.1007/978-1-62703-026-7_40
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-025-0
Online ISBN: 978-1-62703-026-7
eBook Packages: Springer Protocols